CIK 0001709941 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BioAge Labs, Inc.
Sign in to watch- Ticker
- BIOA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474721157
- Phone
- 510-806-1445
- Business address
- 5885 HOLLIS STREET, SUITE 370, EMERYVILLE, CA, 94608
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-17 | Fortney Kristen Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +330,000 | 330,000 | ||
| 2026-02-17 | Barton Shane Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2026-02-17 | RUBIN PAUL D Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2026-02-17 | GOLDSTEIN DOV A MD Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2026-02-02 | RUBIN PAUL D Chief Medical Officer | Option exercise 10b5-1 | +5,433 | $4.11 | $22K | 5,433 |
| 2026-02-02 | RUBIN PAUL D Chief Medical Officer | Option exercise 10b5-1 | +2,000 | $6.57 | $13K | 7,433 |
| 2026-02-02 | RUBIN PAUL D Chief Medical Officer | Sale 10b5-1 | −7,433 | $18.75 | $139K | 0 |
| 2026-02-02 | RUBIN PAUL D Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,433 | 10,870 | ||
| 2026-02-02 | RUBIN PAUL D Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,000 | 5,383 | ||
| 2026-02-01 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise | +3,541 | $4.38 | $16K | 29,491 |
| 2026-02-01 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −3,541 | 162,917 | ||
| 2026-01-16 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | 25,950 |
| 2026-01-16 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −3,542 | 166,458 | ||
| 2026-01-13 | Fortney Kristen Chief Executive Officer | Sale 10b5-1 | −233,107 | $18.12 | $4.2M | 976,949 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise 10b5-1 | +27,000 | $8.39 | $227K | 49,408 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale 10b5-1 | −8,974 | $18.43 | $165K | 40,434 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale 10b5-1 | −4,440 | $19.45 | $86K | 35,994 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale 10b5-1 | −11,663 | $20.54 | $240K | 24,331 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale 10b5-1 | −1,923 | $21.08 | $41K | 22,408 |
| 2026-01-13 | GOLDSTEIN DOV A MD Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 92,587 |
Page 3 of 7 · 124 trades